ADDF In The Media

PharmaTimes - Transatlantic Partnership Pools US$3 Million for Alzheimer’s Drug Discovery

01/28/2014

A transatlantic partnership is putting US$3 million into research projects aimed at repurposing existing drugs as potential therapies for Alzheimer’s disease and related dementias. The US-based Alzheimer’s Drug Discovery Foundation (ADDF), which describes itself as a “biomedical venture philanthropy”, is pooling resources with the UK’s Alzheimer’s Society in an effort to accelerate critical development programmes and bring new treatments to patients.

Sunnybrook Health Sciences Centre - New Support for Alzheimer’s Drug Research

01/28/2014

A trial led by Sunnybrook's Dr. Sandra Black investigating the potential for hypertension drugs to slow Alzheimer's disease progression is receiving support from a new funding collaboration between the Alzheimer's Drug Discovery Foundation of Canada and The W. Garfield Weston Foundation.

Alzheimer’s & Dementia Weekly - Drug Repurposing Aims for New Alzheimer’s Drugs, Faster

01/26/2014

Drug repurposing takes drugs that were already approved for one disease and re-develops them to see if they can help with a different one. This is obviously a much faster process than developing a new drug from scratch. The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society (UK) announced a new partnership that will provide funding for drug-repurposing research in Alzheimer's disease and related dementias. Their stated goal is the acceleration of critical development programs and the bringing ofnew treatments to patients.

Philanthropy News Digest - Alzheimer’s Drug Discovery Foundation Invites Letters of Intent

01/03/2014

Alzheimer’s disease treatments have been shown to be safe and have some positive effect when tested in animal models. However, many of these potentially successful drugs have not been brought to human trials because of the increased cost and risk. The Alzheimer’s Drug Discovery Foundation is responding to this problem through the Program to Accelerate Clinical Trials, an initiative to increase the number of innovative drugs tested in humans for Alzheimer’s disease, related dementias, and cognitive aging. The program will fund biomarker-based pilot clinical trials for Alzheimer’s disease and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. ADDF also is interested in supporting targeted pharmacological and non-pharmacological approaches to prevention and clinical biomarker development programs.

Alzheimer’s Research Forum - A Bird’s-Eye View of Alzheimer’s Research

10/04/2013

As research on Alzheimer's disease becomes a growing societal priority worldwide, the National Institute on Aging and the Alzheimer's Association have launched the International Alzheimer's Disease Research Portfolio (IARDP). By organizing thousands of studies on AD into one central database, IADRP will help sponsors identify funded research to avoid duplication, coordinate funding efforts, and spot gaps in support. Researchers may find it useful for the same reasons. With the participation of nine funding agencies and four more that joined recently, the organizers aim to create a comprehensive overview of global efforts to fund Alzheimer's research.

Metabolic Solutions presents Phase 2a clinical trial results at 14th International ADDF Conference

09/09/2013

Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September 9 at the 14th International Conference on Alzheimer's Drug Discovery. In people with dementia due to Alzheimer's disease (AD) who were not diabetic, the study found that the mTOT(TM)-modulating insulin sensitizer (MSDC-0160) maintained glucose metabolism in key regions of the brain associated with cognitive decline due to AD, as confirmed by FDG-PET imaging.

The Hill: Medicare Proposes a Barrier to an Innovative Alzheimer’s Diagnostic Tool

08/07/2013

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) issued a draft Decision Memorandum to deny Medicare reimbursements to patients using an innovative FDA-approved Alzheimer's diagnostic technology designed to help physicians identify whether patients with signs of cognitive impairment may have Alzheimer's or are in fact suffering from another form of dementia. This information is vital to patients, their providers, choices regarding their treatment and their ultimate health outcomes.

Pharma.com: Academia, Early-Stage Biotech Companies Increasingly Look to CROs to Fill Gap

07/02/2013

Academia, Early-Stage Biotech Companies Increasingly Look to CROs to Fill Gaps

Academia and early-stage biotech companies are more frequently looking to fill holes in their expertise and preclinical capacities through the use of CROs, according to a commentary in Nature Reviews Drug Discovery.

MedCity News: Alzheimer’s drug developers get their own version of Match.com for CROs

07/01/2013

Big pharma’s move to outsource much of its research and development needs to contract research organizations have helped create a thriving CRO industry. The Alzheimer’s Drug Discovery Foundation wants to help academic institutions and small biotechnology companies connect with CROs to make drug development more efficient. It’s launched a social network it compares to Match.com so drug developers can more easily find people and companies that can support their preclinical development work.

Genetic Engineering & Biotechnology News: Seeking New Tools Against Alzheimer’s

06/10/2013

With just five successes, all just slowing progression of symptoms for six to 12 months, the road to an Alzheimer’s drug has been paved with failure. And the setbacks keep coming, most recently in May, when Baxter International’s Gammagard failed in Phase III to reduce cognitive decline or preserve functional ability in mild-to-moderate Alzheimer’s patients.